Free Trial

OS Therapies Q2 2024 Earnings Report

OS Therapies logo
$1.95 -0.65 (-25.00%)
As of 04:00 PM Eastern

OS Therapies EPS Results

Actual EPS
-$0.26
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

OS Therapies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OS Therapies Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

OS Therapies Earnings Headlines

OS Therapies Inc trading resumes
22x better than Bitcoin… WITHOUT crypto
We’re on the verge of a massive paradigm shift. And it will leave millions of people behind… including you, perhaps. The legendary former hedge fund manager Larry Benedict has discovered a different way to make money from Bitcoin.
OS Therapies price target raised to $15 from $8 at Maxim
See More OS Therapies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OS Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OS Therapies and other key companies, straight to your email.

About OS Therapies

OS Therapies (NYSE:OSTX)orporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

View OS Therapies Profile

More Earnings Resources from MarketBeat